LABT · Lakewood-Amedex Biotherapeutics Inc. · Insider Trading
$0.85
-0.08 (-8.33%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has historically incurred recurring operating losses and negative operating cash flows and expects to continue to incur operating losses and consume cash as it executes its business plan. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed financial statements are issued. Because the Company will require additional financing within one year after the date these condensed financial statements are issued and such financing is not considered probable under the provisions of ASC 205-40, management has concluded that its plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$3.96M
Shares
2.37M
Volume · Oct 5
273.51K
Avg daily vol (3M)
2.34M
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-04-24 | Tucker Joseph Edward |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Warrant to acquire Common Stock (Direct)
The warrants vest in four equal tranches of 8,446 warrants each on October 24, 2026, April 24, 2027, October 24, 2027, and April 24, 2028. |
Warrant to acquire Common Stock
|
33,784 |
Legend
Buy — open-market purchase
Sell — open-market sale
↑ Shares acquired
↓ Shares disposed (gift, conversion, tax…)
Showing 1–1 of 1 transactions